Andriy Sergienko, Lyubomyr Lytvynchuk (Kyiv, Ukraine)


Intravitreal bevacizumab (Avastin) is a new and safe surgical treatment for choroidal neovascularization due pathologic myopia (myopic CNV). It allows controlling CNV activity and does not lead to development of foveal chorioretinal atrophy. In some cases, it results in almost complete CNV involution.


Twenty-five eyes of 25 patients with myopic CNV were treated with 1.25 mg of intravitreal bevacizumab. Best corrected visual acuity (BCVA), OCT, FA and central visual field test were performed prior to treatment and postoperatively. A few patients required multiple intravitreal injections. Postoperative visits were scheduled at 1, 6 and 15 months.

Effectiveness / Safety:

The long-term results showed an increase of BCVA (from a mean of 0.1 to 0.37 by Shevaliov chart), a decrease of macular thickness at OCT (from a mean of 295 μn to 256 μn and 237 μn) and a decrease of dye leakage at FA. The treatment modality shows safe and long-lasting effects.

Take home message:

Recent published data and the results of our laboratory tests (bevacizumab cytotoxicity was assessed on fibroblast-like cell strain in vitro), the questions of drug dosage, safety and frequency of injections arise. Chorioretinal dystrophy is a common condition in pathologic myopia. Safety of any treatment modality has to be evaluated carefully and individual approach has to be chosen.